These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 11972391

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB, Zhang Y, Frenkel GD.
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
    Mistry P, Loh SY, Kelland LR, Harrap KR.
    Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583
    [Abstract] [Full Text] [Related]

  • 5. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G, Zeller WJ.
    Anticancer Res; 1991 Nov 11; 11(6):2231-7. PubMed ID: 1776864
    [Abstract] [Full Text] [Related]

  • 6. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 11; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 7. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
    Sharp SY, Smith V, Hobbs S, Kelland LR.
    Br J Cancer; 1998 Jul 11; 78(2):175-80. PubMed ID: 9683290
    [Abstract] [Full Text] [Related]

  • 8. [Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine].
    Kudoh K, Kita T, Hirata J, Ishii K, Hiramatsu H, Kikuchi Y, Nagata I.
    Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jun 11; 46(6):525-32. PubMed ID: 8040625
    [Abstract] [Full Text] [Related]

  • 9. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.
    van Brussel JP, Oomen MA, Vossebeld PJ, Wiemer EA, Sonneveld P, Mickisch GH.
    BJU Int; 2004 Jun 11; 93(9):1333-8. PubMed ID: 15180633
    [Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
    Yellepeddi VK, Vangara KK, Kumar A, Palakurthi S.
    Anticancer Res; 2012 Sep 11; 32(9):3651-8. PubMed ID: 22993302
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
    Bier H.
    Laryngorhinootologie; 1990 Jan 11; 69(1):16-20. PubMed ID: 2310456
    [Abstract] [Full Text] [Related]

  • 13. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL, Hwang J, Perng RP, Whang-Peng J.
    Oncol Res; 1995 Jan 11; 7(1):31-8. PubMed ID: 7549042
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo.
    Bier H.
    Acta Otolaryngol; 1991 Jan 11; 111(4):797-806. PubMed ID: 1950544
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
    Fruehauf JP, Zonis S, al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC.
    Pigment Cell Res; 1997 Aug 11; 10(4):236-49. PubMed ID: 9263331
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.
    Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken PM.
    J Urol; 1990 Sep 11; 144(3):755-9. PubMed ID: 1974934
    [Abstract] [Full Text] [Related]

  • 20. Modulation by D,L-buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines.
    Mans DR, Schuurhuis GJ, Treskes M, Lafleur MV, Retèl J, Pinedo HM, Lankelma J.
    Eur J Cancer; 1992 Sep 11; 28A(8-9):1447-52. PubMed ID: 1325177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.